A study of the immune response to vaccination in MS patients treated w
A study of the immune response to vaccination in MS patients treated with alemtuzumab
What it found
The trial ended early for another reason (see below).
What it measured
Main measures
The primary outcome measure will be the antibody response to each vaccine measured at 4 weeks (+/- 7 days) post-vaccination.
Immune response
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: • Male or non-pregnant, non-lactating female patients, 18 to 50 years of age (inclusive) Exclusion: • Previously received Haemophilus b or pneumococcal vaccines or have had Haemophilus or pneumococcal disease (these antigens are intended to be novel to the subject’s immune system)
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The aim of the trial is to determine if vaccinations are effective in patients with multiple sclerosis who have been treated with the lympho-depleting humanised monoclonal antibody alemtuzumab. The primary outcome measure will be the antibody response to each vaccine measured at 4 weeks post-vaccination.
Papers
Loading reviews and guidelines…
History
Started
Apr 2009